Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-89

Here's my take:

1. Great result "60% reduction in death" which was "the pre-specified endpoint of cardiac death"
2. But "no reduction in non-fatal recurrent decompensated heart failure events, which was the trials primary endpoint"

Point 2 worried me until rereading, specifically "This suggests that rexlemestrocel-L reduces mortality by mechanisms that are distinct from those of existing drugs that reduce hospitalization rates but do not significantly impact cardiac mortality"

I interpret this to mean that there is no real benefit over existing medications in terms of recurring events, BUT a huge benefit of 60% of not dying from the disease.

If I have interpreted this correctly, then I'll take those odds any day.